| Name | Title | Contact Details |
|---|
evolv is the leader in data & ai business transformation, driving value realization to enable your organizations most strategic initiatives. Our solutions offerings include Strategic Execution, Transformation & Adoption, Data Cloud Modernization, Innovation & Design, and Artificial Intelligence. evolv proactively partners with third parties, including AWS, Microsoft, and Snowflake, with whom we are an Elite Services Partner, to bring the best solutions to our clients. Our team applies a breadth of experience to reveal a wholistic view, optimal use cases, and common mistakes to ultimately achieve accelerated results. evolv has been named to the Inc. 5000 list, a list that recognizes the fastest growing private companies in America. Through 2024, evolv has been the Black Diamond Sponsor for Snowflakes Data 4 Breakfast events in Dallas, Houston, and Austin, as well as the Black Diamond Sponsor for the upcoming Snowflake World Tour in Dallas and Chicago. evolv was a Green Circle Sponsor for the Snowflake Data Cloud Summit in San Fransisco in June 2024, as well as multiple sponsorships with Data.World, ARCET Global, and Matillion.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Pendrick Capital Partners is one of the largest HEALTHCARE debt buyers in the USA providing additional revenue streams to all our clients. Our management team is comprised of industry veterans with over 80 years of combined knowledge. We bring core expertise to all consumer debt segments in our underwriting and servicing processes. We hold ourselves to the highest standards and take pride in our business relationships. Our commitment to customer service is unmatched in the industry, just ask for our references. The sale of aged A/R among HEALTHCARE providers has become much more mainstream over the last 10 years. During the last 3 years, Pendrick Capital Partners has purchased over 55 million accounts with a face value of over $16 billion. These portfolios represent patient accounts at ER physician groups, ambulance companies and hospitals. The desire of providers to implement a profitable, compliant, and sensible solution to their revenue cycle challenges and cash acceleration needs has never been greater. With the right partner, the impact of selling should be no different than the impact of using contingency collection agencies to recover delinquent accounts. In many cases, clients have informed us that this practice has enhanced overall collections, as it creates an expectation of payment within their patient bases. Pendrick Capital Partners recognizes the important role that physicians, clinics and hospitals play in local communities and conducts its business with the highest degree of professionalism and respect for patients and clients. Careful due diligence helps us understand an organization`s unique needs and ensures that our tailored collection efforts meet our clients expectations prior to starting a relationship. We do not resell accounts and strongly recommend that any healthcare provider who is concerned about patient and community relations makes a no-resale provision a non-negotiable part of its business agreement with any debt buyer.
K2 Integrity is the preeminent risk, compliance, investigations, and monitoring firm—built by industry leaders, driven by interdisciplinary teams, and supported by cutting-edge technology to safeguard our clients operations, reputations, and economic security. K2 Integrity represents the merger of K2 Intelligence, an industry-leading investigative, compliance, and cyber defense services firm founded in 2009 by Jeremy M. Kroll and Jules B. Kroll, the originator of the modern corporate investigations industry, and Financial Integrity Network (FIN), a premier strategic advisory firm founded by Juan Zarate and Chip Poncy dedicated to helping clients achieve their financial integrity goals. K2 Integrity leverages unmatched multidisciplinary experience to develop cutting-edge solutions, stimulate business opportunities, and shape global economic security in a complex world. Whether its protecting clients assets or navigating the complex financial regulatory landscape to help clients identify, manage, and mitigate risk, K2 Integrity is an advisor trusted to meet and exceed clients goals in a rapidly changing world. To learn more about how K2 Integrity is revolutionizing the management of risk, visit our website, www.k2integrity.com.
LTCG is a leading provider of business process outsourcing for the insurance industry. The nations largest insurers rely on our unparalleled expertise to help manage their complex long-term care portfolios and maximize financial performance. We also provide clients with advanced risk management insight built upon our unique and proprietary long-term care underwriting and claims databases. LTCG has more than 1.4 million long-term care policies currently under its management, representing nearly 20% of all active policies. We serve over 50 national carriers, including every one of the top 10 insurers in the long-term care market. Our experienced management team, which has worked together for years, includes some of the most recognized and respected leaders in the long-term care industry. And our information systems have been developed specifically to support the intricacies of this unique market. To learn more, visit www.ltcg.com